The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

Shares of Eli Lilly & Co. LLY sank 0.08% to $795.67 Tuesday, on what proved to be an all-around favorable trading session for ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...

Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug ...

Yahoo Finance host Akiko Fujita highlights three of the top trending stocks and stories as part of today's Market Minute.

根据Bernstein的分析，Eli Lilly（LLY）在选举后的下跌可能被夸大了，因为当选总统特朗普的一位亲密盟友似乎支持减肥药物。这家制药公司的股票自选举日以来已下跌超过6%，这也导致了整个行业许多公司股价下跌的部分因素。特朗普宣布将Robert F. Kennedy Jr.任命为领导卫生与公共服务部的候选人后，Eli ...

What Eli Lilly ( LLY -0.05%) is doing is far more impressive. The company has been increasing its dividend at a high rate, ...

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...

Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...

A new study put Eli Lilly's Zepbound and Novo Nordisk's Wegovy to the test. Here's which one will help you lose more weight.